These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38721770)

  • 21. The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands.
    Zhang H; Zhang M; Zheng YC; Zhang JG; Xu H
    Bioorg Chem; 2021 Sep; 114():105120. PubMed ID: 34216895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions.
    Jin W; Tan H; Wu J; He G; Liu B
    Drug Discov Today; 2022 Jan; 27(1):246-256. PubMed ID: 34438075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
    Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
    Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
    Yin C; Jia S; Yang X; Wu L
    Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
    Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
    Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
    Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
    Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
    Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells.
    Yang GJ; Song YQ; Wang W; Han QB; Ma DL; Leung CH
    Bioorg Chem; 2021 Sep; 114():105158. PubMed ID: 34378541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
    Mu J; Sun P; Ma Z; Sun P
    J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting BRD4 with PROTAC degrader ameliorates LPS-induced acute lung injury by inhibiting M1 alveolar macrophage polarization.
    Li D; Deng Y; Wen G; Wang L; Shi X; Chen S; Chen R
    Int Immunopharmacol; 2024 May; 132():111991. PubMed ID: 38581996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
    Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.
    Yu J; Yang Y; Zhou R; Tao Y; Zhu F; Jiao W; Zhang Z; Ji T; Li T; Fang F; Xie Y; Wu D; Zhuo R; Li X; Chen Y; Yin H; Wang J; Pan J
    Carcinogenesis; 2024 Jun; 45(6):424-435. PubMed ID: 38302114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
    Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
    Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Shi C; Ye Z; Han J; Ye X; Lu W; Ji C; Li Z; Ma Z; Zhang Q; Zhang Y; He W; Chen Z; Cao X; Shou X; Zhou X; Wang Y; Zhang Z; Li Y; Ye H; He M; Chen H; Cheng H; Sun J; Cai J; Huang C; Ye F; Luo C; Zhou B; Ding H; Zhao Y
    Neuro Oncol; 2020 Aug; 22(8):1114-1125. PubMed ID: 32246150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Privileged Scaffolds Targeting Bromodomain-containing Protein 4.
    Wang R; Wang YA; Xu YG; Shi L
    Curr Top Med Chem; 2022; 22(7):600-627. PubMed ID: 35139799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.